The article by Liu et al entitled “Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors” (JCO Oncology Practice 10.1200/OP-25–00024) was published online June 12, 2025, with errors.
Changes were required to Table 1 and the Acknowledgements section according to the NCI policy on SEER papers:
Table 1.
Baseline cohort characteristics % (n)
| Diabetes | Acute Care Use (6 mo) | ||||||
|---|---|---|---|---|---|---|---|
| All (n=2697) | Yes (n=469) | No (n=2228) | P-value | Yes (n=791) | No (n=1906) | P-value | |
| NCI Index (mean±SD) | 0.39±0.53 | 0.49±0.58 | 0.26±0.45 | <0.0001** | 0.43±0.57 | 0.26±0.44 | <0.001** |
| Age | 75.0±7.0 | 75.3±6.9 | 75.0±7.0 | 0.32 | 75.7±7.1 | 74.6±6.9 | 0.0008** |
| Race | |||||||
| White | 80.3 (2165) | 80.2 (376) | 80.3 (1789) | 0.64 | 80.7 (638) | 80.1 (1527) | 0.78 |
| Black | 12.1 (326) | 11.3 (53) | 12.3 (273) | 12.3 (97) | 12.0 (229) | ||
| Other | 7.6 (205) | 8.5 (40) | 7.5 (166) | 7.1 (56) | 7.9 (150) | ||
| Marital Status | |||||||
| Married | 63.1 (1703) | 62.5 (293) | 63.3 (1410) | 0.89 | 62.7 (496) | 63.3 (1207) | 0.01* |
| Unmarried | 29.3 (789) | 29.4 (138) | 29.2 (651) | 5.6 (44) | 8.5 (161) | ||
| Unknown | 7.6 (205) | 8.1 (38) | 7.5 (167) | 31.7 (251) | 28.2 (538) | ||
| Region | |||||||
| East | 39.3 (1061) | 45.0 (211) | 38.2 (850) | 0.002** | 42.0 (332) | 38.3 (729) | 0.032* |
| Northern Plains | 10.9 (294) | 13.0 (61) | 10.5 (233) | 11.9 (94) | 10.5 (200) | ||
| Pacific Coast | 44.9 (1211) | 38.6 (181) | 46.3 (1030) | 40.6 (321) | 46.7 (890) | ||
| Southwest | 4.9 (131) | 3.4 (16) | 5.2 (115) | 5.6 (44) | 4.6 (87) | ||
| Socioeconomic status | |||||||
| Non-High School >10% | 50.5 (1358) | 54.8 (257) | 49.5 (1101) | 0.038* | 50.0 (396) | 50.6 (962) | 0.83 |
| Non High School <10% | 49.6 (1334) | 45.2 (212) | 50.5 (1122) | 50.0 (394) | 49.4 (940) | ||
| ARSI Treatments | |||||||
| Abiraterone | 76.2 (2056) | 72.7 (1715) | 77.0 (341) | 0.048* | 75.3 (596) | 76.6 (1460) | 0.49 |
| Enzalutamide | 71.1 (1918) | 69.7 (327) | 71.4 (1591) | 0.46 | 66.3 (524) | 73.1 (1394) | 0.0003** |
| Apalutamide | 0.7 (20) | n<11 | 0.7 (16) | 0.76 | n<11 | 1.0 (19) | 0.02* |
| Prior ADT | |||||||
| ADT Prior to ARSI | 85.3 (2300) | 85.3 (400) | 85.3 (1900) | 0.99 | 85.2 (674) | 85.3 (1626) | 0.95 |
| No ADT Prior to ARSI | 14.7 (397) | 14.7 (69) | 14.7 (328) | 14.8 (117) | 14.7 (280) | ||
P<0.05,
P<0.01, comparison between groups
1) No precise recording of n values < 11 are allowed. In Table 1 the row for apalutamide should include n<11 instead of the numbers “4” and “1”, and the percentages were removed.
2) SEER-Medicare should be included in the Acknowledgements section:
This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under cooperative agreement 1NU58DP007156; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors.
This has been corrected as of [Production to add correction date]. The authors apologize for the errors.